In Brief: St. Jude Medical
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical: Firm's Passive Plus DX passive-fixation, steroid eluting pacing lead gains FDA approval, the company announces Feb. 5. The new lead further expands the St. Jude Cardiac Rhythm Management Division portfolio of pacing leads -- the Tendril DX active-fixation, steroid-eluting lead debuted last year...